ARCHIVES

New Drug Approvals Point To Greater Role Of Randomization In Cancer Clinical Trials. European Standards Will Demand More Rigor.

This article is from The Cancer Letter archive.

Vol. 32 No. 07 | February 24, 2006

Download PDF Visit The Full Archive

Related Articles

FDA News: ODAC Clears Photofrin For Microinvasive NSCLC

September 26, 1997

Crizotinib Eliminated Tumors In 7 of 8 Children with ALCL

May 25, 2012

White House appoints NCI Director Andrew von Eschenbach acting FDA commissioner after Lester Crawford resigns.

September 30, 2005

AACI To Become More Aggressive In Developing National Issues; Planning To Start on Collaborate Diagnosis Network

July 15, 1983

Resolutions Urge Doubling Of NIH Budget From ’98 Level.

March 9, 2001

Breast Cancer Risk Rises To 1 Woman In 9

February 1, 1991